The 340B drug discount program is back in court — again. AbbVie, Bristol-Myers Squibb, and Boehringer Ingelheim have filed motions to intervene in the American Hospital Association's lawsuit against HHS over a pilot that would replace upfront drug discounts with post-purchase rebates. Drugmakers argue the government can't adequately represent their financial interests, citing hundreds of millions in losses from duplicate discounts.
The legal tug-of-war over the 340B drug discount program is heating up — for the second time. The Trump administration's revamped pilot, which would swap upfront drug discounts for post-purchase rebates, is facing a fresh lawsuit from the American Hospital Association and safety-net hospitals who argue the switch would impose unsustainable administrative costs and threaten their financial viability. Hospitals estimate true administrative costs could exceed $1 billion annually — nearly double HRSA's $537 million estimate — while many would need to dip into thin cash reserves to pay for drugs upfront before rebates arrive.
Now, three major pharmaceutical companies — AbbVie, Bristol-Myers Squibb, and Boehringer Ingelheim — are asking the court to let them join the fight, arguing HHS alone can't adequately defend their financial interests. PhRMA, the industry's largest trade group, has filed a separate motion to intervene as well. A judge previously denied similar requests in the first round of litigation, but drugmakers say that outcome proved their point: HHS ultimately consented to scrapping the pilot without fully accounting for manufacturers' losses.
By the Numbers:
Why it matters: The 340B program is a financial lifeline for safety-net hospitals serving low-income and uninsured patients. The outcome of this legal battle could reshape how billions of dollars in drug discounts flow through the U.S. healthcare system — with major implications for hospital finances, drug pricing, and patient access to care.
